Palavras-chave
Melitina
Veneno de abelha
Apoptose
Atividade antitumoral
Resumo
O câncer colorretal está entre as neoplasias de maior incidência e mortalidade no mundo e representa um importante problema de saúde pública. Embora cirurgia, quimioterapia e radioterapia sejam amplamente utilizadas, limitações como efeitos adversos e resistência tumoral reforçam a necessidade de investigar novas estratégias terapêuticas. Nesse contexto, a melitina, principal componente peptídico do veneno da abelha Apis mellifera, tem despertado interesse por sua atividade antitumoral experimental. Este estudo teve como objetivo analisar as evidências disponíveis sobre a atividade antitumoral da melitina no câncer colorretal, com ênfase nos mecanismos de ação e nas perspectivas terapêuticas. Foi realizada uma revisão integrativa da literatura, com buscas nas bases PubMed, Web of Science e ScienceDirect, utilizando descritores relacionados à melitina, ao veneno de abelha e ao câncer colorretal. A literatura examinada aponta efeitos sobre a integridade das membranas celulares, a viabilidade tumoral e mecanismos de morte celular, incluindo a apoptose; também foram identificadas investigações sobre migração, invasão, metástase e sistemas de liberação direcionada. Entretanto, parte dos estudos utiliza veneno de abelha completo ou modelos de outros tipos de câncer, devendo ser interpretada como evidência complementar. Os achados são predominantemente pré-clínicos e não demonstram eficácia ou segurança em seres humanos. Conclui-se que a melitina apresenta potencial antitumoral experimental, mas sua aplicação clínica depende de estudos adicionais sobre seletividade, toxicidade, farmacocinética e eficácia.
Referências
AYLANC, Volkan et al. Targeted co-delivery of bee venom and chemotherapeutics via natural sporopollenin microcapsules potently suppresses breast and colorectal cancer cells. Journal of Drug Delivery Science and Technology, v. 124, art. 108605, 2026. DOI: https://doi.org/10.1016/j.jddst.2026.108605.
BADAWI, Jasmin Katrin. Bee venom components as therapeutic tools against prostate cancer. Toxins, v. 13, n. 5, art. 337, 2021. DOI: https://doi.org/10.3390/toxins13050337.
CHENG, Bei; XU, Peisheng. Redox-sensitive nanocomplex for targeted delivery of melittin. Toxins, v. 12, n. 9, art. 582, 2020. DOI: https://doi.org/10.3390/toxins12090582.
CUI, Ziyan et al. Melittin and phospholipase A2: promising anti-cancer candidates from bee venom. Biomedicine & Pharmacotherapy, v. 179, art. 117385, 2024. DOI: https://doi.org/10.1016/j.biopha.2024.117385.
DUAN, Xuefeng et al. Melittin-incorporated nanomedicines for enhanced cancer immunotherapy. Journal of Controlled Release, v. 375, p. 285–299, 2024. DOI: https://doi.org/10.1016/j.jconrel.2024.08.047.
DUARTE, Diana et al. Honeybee venom synergistically enhances the cytotoxic effect of CNS drugs in HT-29 colon and MCF-7 breast cancer cell lines. Pharmaceutics, v. 14, n. 3, art. 511, 2022. DOI: https://doi.org/10.3390/pharmaceutics14030511.
DUFFY, Ciara et al. Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. npj Precision Oncology, v. 4, art. 24, 2020. DOI: https://doi.org/10.1038/s41698-020-00129-0.
GAJSKI, Goran; LEONOVA, Elina; SJAKSTE, Nikolajs. Bee venom: composition and anticancer properties. Toxins, v. 16, n. 3, art. 117, 2024. DOI: https://doi.org/10.3390/toxins16030117.
GAO, Dongqi et al. Melittin induces NSCLC apoptosis via inhibition of miR-183.
OncoTargets and Therapy, v. 11, p. 4511–4523, 2018. DOI: https://doi.org/10.2147/OTT.S169806.
GUO, Yuxin et al. Metal-phenolic network-facilitated “foe-to-friend” conversion of melittin for cancer immunotherapy with boosted abscopal effect. Research, v. 6, art. 0052, 2023. DOI: https://doi.org/10.34133/research.0052.
GUSMÃO, Lívia Raquel Macedo; BRANDÃO, Jéssica Daniella Damasceno. Fatores de risco relacionados ao câncer colorretal: revisão de literatura e implicações para prevenção. Revista Ibero-Americana de Humanidades, Ciências e Educação, São Paulo, v. 11, n. 11, p. 3438–3450, nov. 2025. DOI: https://doi.org/10.51891/rease.v11i11.22158.
HONARI, Pooyan et al. Highly in vitro anti-cancer activity of melittin-loaded niosomes on non-small cell lung cancer cells. Toxicon, v. 241, art. 107673, 2024. DOI: https://doi.org/10.1016/j.toxicon.2024.107673.
LAURINDO, Lucas Fornari et al. The therapeutic potential of bee venom-derived apamin and melittin conjugates in cancer treatment: a systematic review. Pharmacological
Research, v. 209, art. 107430, 2024. DOI: https://doi.org/10.1016/j.phrs.2024.107430.
LI, Xuan et al. Melittin kills A549 cells by targeting mitochondria and blocking mitophagy flux. Redox Report, v. 28, n. 1, art. 2284517, 2023. DOI: https://doi.org/10.1080/13510002.2023.2284517.
LIM, Haet Nim; BAEK, Seung Bae; JUNG, Hye Jin. Bee venom and its peptide component melittin suppress growth and migration of melanoma cells via inhibition of PI3K/AKT/mTOR and MAPK pathways. Molecules, v. 24, n. 5, art. 929, 2019. DOI: https://doi.org/10.3390/molecules24050929.
LUO, Li et al. Acid-activated melittin for targeted and safe antitumor therapy.
Bioconjugate Chemistry, v. 29, n. 9, p. 2936–2944, 2018. DOI: https://doi.org/10.1021/acs.bioconjchem.8b00352.
LUO, Yan et al. Melittin treatment prevents colorectal cancer from progressing in mice through ER stress-mediated apoptosis. Journal of Pharmacy and Pharmacology, v. 75, n. 5, p. 645–654, 2023. DOI: https://doi.org/10.1093/jpp/rgad008.
LV, Shixian et al. Development of D-melittin polymeric nanoparticles for anti-cancer treatment. Biomaterials, v. 277, art. 121076, 2021. DOI: https://doi.org/10.1016/j.biomaterials.2021.121076.
LYU, Can; FANG, Fanfu; LI, Bai. Anti-tumor effects of melittin and its potential applications in clinic. Current Protein and Peptide Science, v. 20, n. 3, p. 240–250, 2019. DOI: https://doi.org/10.2174/1389203719666180612084615.
MAŁEK, Agata et al. Can bee venom be used as anticancer agent in modern medicine? Cancers, v. 15, n. 14, art. 3714, 2023. DOI: https://doi.org/10.3390/cancers15143714.
MOGHADDAM, Farnaz D. et al. Apoptotic effects of melittin on 4T1 breast cancer cell line is associated with up regulation of Mfn1 and Drp1 mRNA expression. Anti-Cancer Agents in Medicinal Chemistry, v. 20, n. 7, p. 790–799, 2020. DOI: https://doi.org/10.2174/1871520620666200211091451.
NIKODIJEVIĆ, Danijela D. et al. Impact of bee venom and melittin on apoptosis and biotransformation in colorectal carcinoma cell lines. Toxin Reviews, v. 40, n. 4, p. 1272–1279, 2021. DOI: https://doi.org/10.1080/15569543.2019.1680564.
OLIVEIRA, Ana Maria Boaventura de et al. Bee venom and cancer: a mini-review focusing on melittin antitumoral effects. Current Drug Targets, v. 27, n. 9, p. 585–599, 2026. DOI: https://doi.org/10.2174/0113894501424902260115203324.
PANDEY, Pratibha et al. An updated review summarizing the anticancer efficacy of melittin from bee venom in several models of human cancers. Nutrients, v. 15, n. 14, art. 3111, 2023. DOI: https://doi.org/10.3390/nu15143111.
PLASAY, Makkasau; MUSLIMIN, Lukman. Melittin, a potential natural toxin with anticancer properties: regulating IL-1β, COX-2 and TNF-α in human colorectal cancer cells WiDr. Trends in Sciences, v. 21, n. 4, art. 7424, 2024. DOI: https://doi.org/10.48048/tis.2024.7424.
RADY, Islam et al. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Letters, v. 402, p. 16–31, 2017. DOI: https://doi.org/10.1016/j.canlet.2017.05.010.
RAID, Fernando Carvalho et al. Câncer colorretal: da base genética ao diagnóstico e manejo terapêutico. Revista Foco, v. 18, n. 11, art. e10636, 2025. DOI: https://doi.org/10.54751/revistafoco.v18n11-166.
RIFI, Mariam et al. Synergistic cytotoxic effect of Apis mellifera syriaca venom and
Jania rubens polysaccharide extract on HCT-116 and HT-29 colon cancer cell lines. The Natural Products Journal, v. 16, n. 1, art. e22103155359674, 2026. Publicado on-line em 12 mar. 2025. DOI: https://doi.org/10.2174/0122103155359674250306055130.
RIZKALLAH, J. et al. Melittin-based nanoparticles for cancer therapy: mechanisms, applications, and future perspectives. Pharmaceutics, v. 17, n. 8, art. 1019, 2025. DOI: https://doi.org/10.3390/pharmaceutics17081019.
ROCHA, Mackson Martins et al. A new therapeutic approach for bone metastasis in colorectal cancer: intratumoral melittin. Journal of Venomous Animals and Toxins Including Tropical Diseases, v. 28, art. e20210067, 2022. DOI: https://doi.org/10.1590/1678-9199-JVATITD-2021-0067.
SAGHI, Hossein et al. Bee venom induces anti-tumor effects in HT-29 colon cancer cells through regulation of cell proliferation and apoptosis. Biologia, v. 77, n. 12, p. 3595–3602, 2022. DOI: https://doi.org/10.1007/s11756-022-01201-9.
SOLIMAN, Caroline et al. The membrane effects of melittin on gastric and colorectal cancer. PLOS ONE, v. 14, n. 10, art. e0224028, 2019. DOI: https://doi.org/10.1371/journal.pone.0224028.
TIPGOMUT, Chartsiam et al. Melittin induced G1 cell cycle arrest and apoptosis in
Chago-K1 human bronchogenic carcinoma cells and inhibited the differentiation of THP-1 cells into tumour-associated macrophages. Asian Pacific Journal of Cancer Prevention, v. 19, n. 12, p. 3427–3434, 2018. DOI: https://doi.org/10.31557/APJCP.2018.19.12.3427.
WANG, Anqi et al. Melittin-based nano-delivery systems for cancer therapy.
Biomolecules, v. 12, n. 1, art. 118, 2022. DOI: https://doi.org/10.3390/biom12010118.
WANG, Kangli et al. Melittin inhibits colorectal cancer growth and metastasis by activating the mitochondrial apoptotic pathway and suppressing epithelial-mesenchymal transition and angiogenesis. International Journal of Molecular Sciences, v. 25, n. 21, art. 11686, 2024. DOI: https://doi.org/10.3390/ijms252111686.
XIONG, Yuezhihong et al. Nanocarrier-enabled melittin therapy: mechanistic advances, therapeutic applications, and translational challenges. International Journal of
Nanomedicine, v. 21, art. 599827, 2026. DOI: https://doi.org/10.2147/IJN.S599827.
YAACOUB, Carole et al. The cytotoxic effect of Apis mellifera venom with a synergistic potential of its two main components—melittin and PLA2—on colon cancer HCT116 cell lines. Molecules, v. 26, n. 8, art. 2264, 2021. DOI: https://doi.org/10.3390/molecules26082264.
YAZDIAN-ROBATI, Rezvan et al. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo. Drug Development and Industrial Pharmacy, v. 45, n. 4, p. 603–610, 2019. DOI: https://doi.org/10.1080/03639045.2019.1569029.
YE, Ran et al. Stable loading and delivery of melittin with lipid-coated polymeric nanoparticles for effective tumor therapy with negligible systemic toxicity. ACS Applied Materials & Interfaces, v. 13, n. 47, p. 55902–55912, 2021. DOI: https://doi.org/10.1021/acsami.1c17618.
YU, Renzhi et al. Melittin suppresses growth and induces apoptosis of non-small-cell lung cancer cells via down-regulation of TGF-β-mediated ERK signal pathway.
Brazilian Journal of Medical and Biological Research, v. 54, n. 2, art. e9017, 2021. DOI: https://doi.org/10.1590/1414-431X20209017.
YU, Xiang et al. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nature Communications, v. 10, art. 574, 2019. DOI: https://doi.org/10.1038/s41467-019-08538-x.
YU, Xiang et al. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nature Communications, v. 11, art. 1110, 2020. DOI: https://doi.org/10.1038/s41467-020-14906-9.
YU, Xiang et al. Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies. Journal of Nanobiotechnology, v. 21, art. 454, 2023. DOI: https://doi.org/10.1186/s12951-023-02223-4.
ZAMANI, Mozhdeh; BOZORG-GHALATI, Farzaneh; MOKARRAM, Pooneh. Melittin
as an activator of the autophagy and unfolded protein response pathways in colorectal HCT116 cell line. Iranian Biomedical Journal, v. 28, n. 1, p. 46–52, 2024. DOI: https://doi.org/10.61186/ibj.3993.
ZHANG, Jianzhong et al. Genetically engineered nano-melittin vesicles for multimodal synergetic cancer therapy. Bioengineering & Translational Medicine, v. 8, n. 6, art. e10482, 2023. DOI: https://doi.org/10.1002/btm2.10482.

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Eduarda Vytória Rizzi de França, Caroline Vitoria de Oliveira, Alessandra Ruyz Medeiros (Autor)